Stock DERM JOURNEY MEDICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News Journey Medical Corporation

Equities

DERM

US48115J1097

Delayed Nasdaq
Other stock markets
 10:35:48 2024-05-14 EDT 		5-day change 1st Jan Change
3.553 USD -0.48% Intraday chart for Journey Medical Corporation +3.28% -38.32%
05-13 Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024
05-13 Journey Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024
Journey Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Posts Q1 Revenue $13M, vs. Street Est of $14.1M
MT
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
AQ
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
AQ
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
AQ
Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer
CI
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
AQ
Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
AQ
Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
CI
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 on Microbial Flora of Healthy Adults At 2024 Annual Meeting
CI
Alliance Global Partners Starts Coverage on Journey Medical With Buy Rating, $8.50 Price Target
MT
Journey Medical Submits New Drug Application to FDA for Rosacea Treatment; Shares Rise
MT
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DERM Stock
  4. News Journey Medical Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW